Johnson & Johnson subsidiary Janssen Pharmaceutical Companies (Janssen) has reported that its Phase IIb FRONTIER 1 clinical trial of JNJ-2113 for plaque psoriasis (PsO) met both its primary and secondary efficacy endpoints after 16 weeks.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,